Role of flow cytometry in the assessment of restoration of hematopoiesis during standard Exjade® treatment in patients with low- intermediate I risk myelodysplastisc syndromes, a pilot study

Role of flow cytometry in the assessment of restoration of hematopoiesis during standard Exjade® treatment in patients with low- intermediate I risk myelodysplastisc syndromes, a pilot study - NVT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON35738

Enrollment

Registered

2011-08-03

Start date

2011-09-29

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

n.a.

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: MDS type low and intermediate risk, supportive care treatment, start Exjade®

Exclusion criteria

Exclusion criteria: Comorbidity, anaemia MDS unrelated, previous treatment with Exjade®

Design outcomes

Primary

Measure	Time frame
see above	—

Secondary

Measure	Time frame
See above	—

Countries

Netherlands

Outcome results